[ET Net News Agency, 18 July 2019] Sino Biopharmaceutical Limited (01177) said the
anti-tumour drug "Abiraterone Acetate Tablet" developed by Chia Tai - Tianqing
Pharmaceutical Group Co. Ltd., a subsidiary of the company, has obtained approval for drug
registration granted by the National Medical Products Administration of the People's
Republic of China. The Abiraterone Acetate Tablet developed by the group was the second of
its type to obtain approval for drug registration in China.
Abiraterone is a selective, irreversible steroid inhibitor of CYP17A1. It prevents
testosterone synthesis in testes, adrenal glands and tumours by inhibiting enzyme
activity. It is applied in combination with prednisone to treat metastatic
castration-resistant prostate cancer. (RC)